Mimosa Therapeutics CEO James Keim tells Proactive the privately-held group, which owns a production facility in the Netherlands, is focused on growing its mycelium-based psilocybin, which he says, are more 'predictable' in its potencies. Keim the group's strategy includes creating full spectrum, natural psychedelics which research organizations can use for replicability, including standardization of potencies.
Mimosa Therapeutics pioneering in the mycelium-based psilocybin space
